You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 24, 2024

ADALAT Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Adalat, and what generic alternatives are available?

Adalat is a drug marketed by Bayer Pharms and Norwich and is included in two NDAs.

The generic ingredient in ADALAT is nifedipine. There are thirty-nine drug master file entries for this compound. Thirty-eight suppliers are listed for this compound. Additional details are available on the nifedipine profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Adalat

A generic version of ADALAT was approved as nifedipine by ACTAVIS ELIZABETH on January 8th, 1991.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for ADALAT?
  • What are the global sales for ADALAT?
  • What is Average Wholesale Price for ADALAT?
Drug patent expirations by year for ADALAT
Drug Prices for ADALAT

See drug prices for ADALAT

Recent Clinical Trials for ADALAT

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Cao YuPhase 1
Jing LiuPhase 4
University of UtahPhase 4

See all ADALAT clinical trials

US Patents and Regulatory Information for ADALAT

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bayer Pharms ADALAT nifedipine CAPSULE;ORAL 019478-001 Nov 27, 1985 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Norwich ADALAT CC nifedipine TABLET, EXTENDED RELEASE;ORAL 020198-002 Apr 21, 1993 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Bayer Pharms ADALAT nifedipine CAPSULE;ORAL 019478-002 Sep 17, 1986 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Norwich ADALAT CC nifedipine TABLET, EXTENDED RELEASE;ORAL 020198-001 Apr 21, 1993 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Norwich ADALAT CC nifedipine TABLET, EXTENDED RELEASE;ORAL 020198-003 Apr 21, 1993 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for ADALAT

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Bayer Pharms ADALAT nifedipine CAPSULE;ORAL 019478-001 Nov 27, 1985 ⤷  Sign Up ⤷  Sign Up
Bayer Pharms ADALAT nifedipine CAPSULE;ORAL 019478-002 Sep 17, 1986 ⤷  Sign Up ⤷  Sign Up
Bayer Pharms ADALAT nifedipine CAPSULE;ORAL 019478-002 Sep 17, 1986 ⤷  Sign Up ⤷  Sign Up
Bayer Pharms ADALAT nifedipine CAPSULE;ORAL 019478-001 Nov 27, 1985 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for ADALAT

See the table below for patents covering ADALAT around the world.

Country Patent Number Title Estimated Expiration
Israel 40165 ⤷  Sign Up
Bulgaria 27728 METOD ZA POLUCHAVANE NA KORONARNO SREDSTVO (METHOD FOR OBTAINING OF CORONAL MEANS) ⤷  Sign Up
Egypt 10633 PROCESS FOR PREPARATION"A CORONARY AGENT IN SPECIAL FORM AND PROCESSES FOR ITS MANUFACTURE" ⤷  Sign Up
Japan S58121211 MANUFACTURE OF INSTANTANEOUS MOUTH DISCHARGING SUBLINGUAL SOFT CAPSULE MEDICINE ⤷  Sign Up
Belgium 787951 ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.